

JANUS HENDERSON GLOBAL LIFE SCIENCES FUND

A Share - All data as at 30 November 2019

Janus Henderson
INVESTORS

Investment Objective and Policy

The Fund's investment objective is to seek long-term growth of capital by investing primarily in equity securities of companies located anywhere in the world and selected for their growth potential.

The Fund will invest primarily in securities of companies that have a life sciences orientation. Companies with a "life sciences orientation" include companies engaged in research, development, production or distribution of products or services related to health and personal care, medicine or pharmaceuticals. The Fund will invest at least 25% of its total assets, in the aggregate, in the following industry groups: health care; pharmaceuticals; agriculture; cosmetics/personal care; and biotechnology. No more than 10% of the net asset value of the Fund may be invested in securities traded on any one developing market and the aggregate amount of the Fund which may be invested in securities traded on the developing markets is 20% of the net asset value of the Fund.

Annualized Performance (%)

	1 M	3 M	YTD	1 Yr	3 Yrs	5 Yrs	10 Yrs	Since Launch
A\$acc	8.05	9.90	22.21	10.91	14.02	6.75	14.69	6.92
A€acc(hgd)	7.88	9.13	18.63	7.27	10.74	4.55	13.12	6.41
Benchmark Index	4.73	9.84	19.18	9.57	14.13	7.22	12.15	7.41

Calendar Year Returns (%)

	2018	2017	2016	2015	2014
A\$acc	2.01	20.55	-13.79	5.69	32.75
A€acc(hgd)	-1.21	17.68	-15.20	5.45	32.63
Benchmark Index	2.51	19.80	-6.81	6.60	18.10

Net Annualized Performance (%)

Net of Initial Sales Charge (Class A)[^]

Class A	1 M	3 M	YTD	1 Yr	3 Yrs	5 Yrs	10 Yrs	Since Launch
A\$acc	2.64	4.39	16.09	5.37	12.10	5.66	14.10	6.64
A€acc(hgd)	2.48	3.67	12.68	1.89	8.86	3.48	12.54	6.13
Benchmark Index	4.73	9.84	19.18	9.57	14.13	7.22	12.15	7.41

Cumulative Return (%)



Fund Facts

Portfolio Manager	Andy Acker, CFA
Base Currency	USD
Domicile	Ireland
Benchmark	MSCI World Healthcare Index
Fund Size (US\$M)	\$2552.4
Dealing	Daily
Published NAV	Bloomberg (Code JANGLA1)

A Share

Initial Sales Charge	Up to 5.00%
Annual Management Fee	1.50%
Overall Morningstar Rating™	★★★★ ¹

Past performance is no guarantee of future results. Source: Morningstar. Basis: total returns, NAV to NAV in USD, with income reinvested.

Performance figures of less than 1 year are not annualized.

Source: The fund data quoted is Janus Henderson Investors unless stated otherwise.

¹Source of star rating: Morningstar, Inc., Sector Equity Healthcare, A-USD Class, as of 30 November 2019.

[^] Assume 5% initial sales charge/front-end load (FEL) applied. (hgd) = hedged

Top 10 Holdings (%)		Industry Breakdown (%)		Country Breakdown (%)	
Merck & Co Inc	4.35	Pharmaceuticals	35.91	United States	79.19
Novartis AG (ADR)	4.29	Biotechnology	25.74	Switzerland	6.73
Abbott Laboratories	3.30	Health Care Equipment	16.49	United Kingdom	3.30
UnitedHealth Group Inc	3.17	Managed Health Care	8.07	Japan	3.25
AstraZeneca PLC	2.99	Life Sciences Tools & Services	5.85	France	2.73
Thermo Fisher Scientific Inc	2.90	Health Care Supplies	3.83	Denmark	1.96
Bristol-Myers Squibb Co	2.67	Health Care Facilities	1.27	Germany	1.23
Takeda Pharmaceutical Co Ltd	2.65	Health Care Services	0.86	Belgium	0.52
Anthem Inc	2.45	Health Care Technology	0.79	Sweden	0.41
Humana Inc	2.45	Health Care Distributors	0.47	Canada	0.03
Total	31.22				
Asset Allocation (%)		Market Capitalization (%)			
Equities	99.28	Over \$100B	35.77		
US Common Stock	78.96	\$50B to \$100B	17.06		
Non-US Common Stock	20.16	\$10B to \$50B	15.97		
Equity Other	0.16	\$5B to \$10B	9.34		
Fixed Income	0.07	\$1B to \$5B	13.39		
Convertibles	0.07	\$500M to \$1B	1.53		
Cash & Equivalents	0.65	\$250M to \$500M	0.43		
		Under \$100M	0.10		
		N/A	5.69		
Fund Characteristics					
Total Number of Holdings	99				
Portfolio Turnover Rate	36.93%				
Weighted Avg. Market Cap (US \$B)	\$83.0				
Median Market Cap (US\$B)	\$8.3				
Fund share class					
	A\$acc	A€acc(hgd)	AAUDacc(hgd)	ACNHacc(hgd)	AHK\$acc
Launch Date	31 Mar 2000	31 Mar 2000	04 Oct 2013	03 Oct 2014	27 Feb 2015
NAV	\$37.30	€33.94	AUD20.01	CNH16.98	HKD12.56
ISIN	IE0009355771	IE0002122038	IE00BF2GM042	IE00BFTCP959	IE00B4R5TH58

Source: Janus Henderson Investors as of 30 November 2019, unless stated otherwise.

Important information

The Fund may employ investment techniques and instruments for investment purposes, such as trading in futures, options and swaps and other financial derivative instruments. Issued in Singapore by Janus Henderson Investors (Singapore) Limited, licensed and regulated by the Monetary Authority of Singapore, Company Registration No. 199700782N. Janus Henderson Capital Funds Plc is a UCITS established under Irish law, with segregated liability between funds. Janus Capital International Limited acts as the investment adviser to JHCF. Janus Capital Management LLC ("Janus") acts as sub-investment adviser of the Fund to Janus Capital International Limited. This is neither an offer nor solicitation to purchase Shares of the Fund. Investors are warned that they should only make their investments based on the most recent offering documents which contains information about fees, expenses and risks, which is available from all distributors and paying agents, and which should be read carefully. An investment in the Fund may not be suitable for all investors and is not available to all investors in all jurisdictions. In particular, it is not available to US persons. The rate of return may vary and the principal value of an investment will fluctuate due to market and foreign exchange movements. Shares, if redeemed, may be worth more or less than their original cost. In preparing this document, Janus Henderson Investors has reasonable belief to rely upon the accuracy and completeness of information available from public sources. Unless otherwise stated, the source of information is from Janus Henderson Investors. It is the intermediary's responsibility to determine the extent it may pass on this document or the information contained in it to any third party under relevant law, and to comply with all such law. Janus Henderson Investors is not responsible for any unlawful distribution of this document to any third parties. Investments are not deposits or other obligations of, guaranteed or insured by Janus Capital International Limited or any distributor or any of their affiliates, or by any local governmental or insurance agency. Effective 1 May 2019, Ethan Lovell is no longer the Co-Portfolio Manager of the Janus Henderson Global Life Sciences Fund, while Andy Acker remains as Portfolio manager of the Fund. Portfolio holdings are subject to change without notice. ©2019 Morningstar. All Rights Reserved. CFA® and Chartered Financial Analyst® are trademarks owned by CFA Institute. ©2019, Janus Henderson Group plc. Janus Henderson is a trademark of Janus Henderson Group plc or one of its subsidiary entities. This advertisement has not been reviewed by the Monetary Authority of Singapore. In Singapore, only available to accredited and institutional investors as defined under section 4A of the Securities and Futures Act (Cap.289), and may not otherwise be distributed in Singapore.